ERBOKRYO® CA - Cryosurgical Unit with Flexible ERBECRYO Probe, 1.9 mm outer diameter (ERBE Inc., Tubingen, Germany) for Non-small Cell Lung Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Non-small Cell Lung CancerERBOKRYO® CA - Cryosurgical Unit with Flexible ERBECRYO Probe, 1.9 mm outer diameter (ERBE Inc., Tubingen, Germany) - Device
Eligibility
22 - 80
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new cancer treatment to see if it is safe and effective.

Eligible Conditions
  • Non-small Cell Lung Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

Study Objectives

2 Primary · 5 Secondary · Reporting Duration: 14 Days

1 Day
Ability of radial endobronchial ultrasound to identify peripheral lung tumor
Feasibility
Length of fluoroscopy exposure during BCI
Length of time to perform BCI
14 Days
Correlation of BAL PD-1 phenotype with peripheral blood
Pre- and Post-BCI peripheral blood analysis
7 Days
Safety

Trial Safety

Safety Progress

1 of 3

Similar Trials

Trial Design

1 Treatment Group

Bronchoscopic Cryo-Immunotherapy (BCI)
1 of 1

Experimental Treatment

24 Total Participants · 1 Treatment Group

Primary Treatment: ERBOKRYO® CA - Cryosurgical Unit with Flexible ERBECRYO Probe, 1.9 mm outer diameter (ERBE Inc., Tubingen, Germany) · No Placebo Group · Phase < 1

Bronchoscopic Cryo-Immunotherapy (BCI)
Device
Experimental Group · 1 Intervention: ERBOKRYO® CA - Cryosurgical Unit with Flexible ERBECRYO Probe, 1.9 mm outer diameter (ERBE Inc., Tubingen, Germany) · Intervention Types: Device

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 14 days

Who is running the clinical trial?

NYU Langone HealthLead Sponsor
1,264 Previous Clinical Trials
753,571 Total Patients Enrolled
Daniel Sterman, MDPrincipal InvestigatorNew York Langone Health
1 Previous Clinical Trials
53 Total Patients Enrolled

Eligibility Criteria

Age 22 - 80 · All Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
The patient must have a pre-procedure chest CT scan with the presence of a bronchus or airway path leading directly to the peripheral lung tumor.
You are able to provide informed consent.
The patient must be free of the following prior to enrollment in the study: prior chemotherapy, radiation therapy, or immunotherapy.
You are undergoing bronchoscopy for diagnostic and/or palliative purpose.